2020
m6A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development
Gao Y, Vasic R, Song Y, Teng R, Liu C, Gbyli R, Biancon G, Nelakanti R, Lobben K, Kudo E, Liu W, Ardasheva A, Fu X, Wang X, Joshi P, Lee V, Dura B, Viero G, Iwasaki A, Fan R, Xiao A, Flavell RA, Li HB, Tebaldi T, Halene S. m6A Modification Prevents Formation of Endogenous Double-Stranded RNAs and Deleterious Innate Immune Responses during Hematopoietic Development. Immunity 2020, 52: 1007-1021.e8. PMID: 32497523, PMCID: PMC7408742, DOI: 10.1016/j.immuni.2020.05.003.Peer-Reviewed Original ResearchConceptsDouble-stranded RNADeleterious innate immune responseMammalian hematopoietic developmentEndogenous double-stranded RNAHematopoietic developmentInnate immune responseAbundant RNA modificationMurine fetal liverPattern recognition receptor pathwaysImmune responseProtein codingDsRNA formationRNA modificationsWriter METTL3Hematopoietic defectsPerinatal lethalityNative stateConditional deletionAberrant innate immune responsesLoss of METTL3Hematopoietic failureReceptor pathwayAberrant immune responsePrevents formationFetal liver
2019
Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
Magni M, Biancon G, Rizzitano S, Cavanè A, Paolizzi C, Dugo M, Corradini P, Carniti C. Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma. British Journal Of Cancer 2019, 121: 567-577. PMID: 31474759, PMCID: PMC6889385, DOI: 10.1038/s41416-019-0557-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCell CycleCell SurvivalCyclophosphamideDasatinibDoxorubicinDrug Administration ScheduleDrug SynergismEtoposideGene ExpressionGene Expression ProfilingHumansJurkat CellsLymphoma, T-CellMice, Inbred NODMice, SCIDPrednisoneProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-fynReceptors, Antigen, T-CellRhoA GTP-Binding ProteinTreatment OutcomeUp-RegulationVincristineConceptsT-cell lymphomaPeripheral T-cell lymphomaDrug combinationsTyrosine kinase inhibitor dasatinibVivo xenograft mouse modelMalignant T-cell linesXenograft mouse modelTyrosine kinase inhibitionTumor growth inhibitionKinase inhibitor dasatinibT cell receptorT cell linesT-cell receptor pathwayCell cycle distributionWestern blot analysisChemotherapy efficacyPreclinical modelsConclusionsOur dataMouse modelVivo effectsXenograft modelClinical testingTreatment resultsInhibitor dasatinibLymphoma
2016
Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation
Gimondi S, Dugo M, Vendramin A, Bermema A, Biancon G, Cavané A, Corradini P, Carniti C. Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation. Experimental Hematology 2016, 44: 624-634.e1. PMID: 27013207, DOI: 10.1016/j.exphem.2016.03.005.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBiomarkersCluster AnalysisCombined Modality TherapyFemaleGene ExpressionGene Expression ProfilingGene Regulatory NetworksGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansLymphomaMaleMicroRNAsMiddle AgedPrognosisReproducibility of ResultsTime FactorsTransplantation, HomologousYoung AdultConceptsAllo-HSCTLymphoma patientsReal-time polymerase chain reactionAcute graftPolymerase chain reactionAllogeneic hematopoietic stem cell transplantationUnrelated hematopoietic stem cellHematopoietic stem cell transplantationHost disease (GVHD) resultsNon-aGVHD patientsStem cell transplantationChain reactionQuantitative real-time polymerase chain reactionRoutine clinical useCutaneous GVHDIntestinal GVHDHost diseaseSignificant morbidityUnrelated donorsCell transplantationPredictive biomarkersMicroRNA expression profileBlood samplingTherapeutic strategiesPatients